<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03596697</url>
  </required_header>
  <id_info>
    <org_study_id>CTRV-CRV431-101</org_study_id>
    <nct_id>NCT03596697</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Partially-blinded, Placebo-controlled, Ascending Sequential Dose Groups, Single Dose Study of the Safety, Tolerability and Pharmacokinetics of CRV431, Alone and In Combination With Tenofovir Disoproxil Fumarate in Healthy Subjects, With a Pilot Study of Multiple Ascending Sequential Doses in Healthy Volunteer Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hepion Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hepion Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is three part study that will, in part one assess the safety, tolerability, and PK of a
      single dose of CRV431 in healthy volunteers. The second part of the study will be a single
      dose drug-drug interaction study in healthy volunteers with CRV431 co-treated with TDF. The
      third part of the study will assess the safety, tolerability, PK, and preliminary signal for
      antiviral efficacy and identification of clinically-relevant biomarkers of CRV431 with TDF in
      stable HBV patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of healthy volunteers and patients with chronic HBV infection with treatment-related adverse events</measure>
    <time_frame>56 days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Infectious Disease</condition>
  <condition>Liver Diseases</condition>
  <arm_group>
    <arm_group_label>CRV431</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Either single or multiple doses of varying dose levels</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TDF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg TDF</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CRV431</intervention_name>
    <description>Single or multiple dose(s) of CRV431</description>
    <arm_group_label>CRV431</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single Placebo dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TDF</intervention_name>
    <description>Single or multiple dose(s) of TDF</description>
    <arm_group_label>TDF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Capable of giving written informed consent

          -  Willing and able to complete all study requirements

          -  Healthy male or female between 18 and 55 years of age (inclusive);

          -  Body mass index 16 to 32 kg/m2 (inclusive);

        Exclusion Criteria:

          -  Positive test for HCVAb or HIVAb. For healthy subjects only: positive test for HBsAg

          -  Current or history of abuse of alcohol or illicit drugs

          -  Received an investigational drug, vaccine or medical device within 90 days prior to
             first dose of study drug.

        Additional Exclusion Criteria for HBV Pilot Subjects Only:

          -  Evidence of significant liver fibrosis or cirrhosis

          -  History of NAFLD or NASH

          -  Positive test for HDV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jill Greytok</last_name>
    <role>Study Director</role>
    <affiliation>ContraVir Pharmaceutical, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kujtesa Klobucista</last_name>
    <phone>732-902-4000</phone>
    <email>kklobucista@contravir.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Celerion, Inc</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Celerion, Inc</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Pinnacle Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Harrison</last_name>
      <phone>210-982-0320</phone>
    </contact>
    <contact_backup>
      <last_name>Gail Hinkson</last_name>
      <phone>210-982-0320</phone>
      <email>mailto:ghinkson@pinnacleresearch.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 3, 2018</study_first_submitted>
  <study_first_submitted_qc>July 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2018</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CRV431</keyword>
  <keyword>Hepatitis B Virus</keyword>
  <keyword>Hepatitis Virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

